

Nanomaterial-Based Antimicrobial Devices

Pierre Nowak¹, Matteo Rossi², Amelia Horvath³

¹ Assistant Professor, School of Data Science, Western Europe Data Science University, Madrid, Spain, Spain. Email: pierre.nowak597@gmail.com | ORCID: 8820-9446-5632-4375

² Postdoctoral Researcher, Department of Machine Learning, Mediterranean Institute of Technology, Rome, Italy, Italy. Email: matteo.rossi578@gmail.com | ORCID: 2989-7381-3887-1292

³ Associate Professor, Department of Computer Science, Advanced Computing University, Paris, France, France. Email: amelia.horvath864@gmail.com | ORCID: 8161-0793-8169-0108

ABSTRACT

Hospital-acquired infections kill tens of thousands of patients every year in Europe alone, and the relentless rise of antibiotic-resistant bacteria has made the problem harder to manage with drugs alone. Nanomaterial-based antimicrobial devices offer a different angle of attack: rather than treating infections after they start, these devices aim to prevent microbial colonisation on surfaces that come into contact with vulnerable tissue -- catheters, wound dressings, implant coatings, and surgical meshes. Silver nanoparticles have been the workhorse of this field for over a decade, but concerns about cytotoxicity at higher loadings and silver ion accumulation have pushed researchers toward alternatives like copper oxide, zinc oxide, graphene derivatives, and chitosan-based nanocomposites. The question for anyone designing or procuring these devices is which nanomaterial platform actually delivers the best balance of antimicrobial potency, host safety, durability, and manufacturability. We examined 200 nanomaterial antimicrobial device programmes across five material classes, collected from laboratories in Spain, Italy, and France between 2019 and 2023, and built a Nanomaterial Antimicrobial Device Quality Index (NADQI) that combines bactericidal efficacy, cytocompatibility margin, coating durability, elution control, and scalability readiness into a single weighted score. NADQI predicted successful clinical translation with $r = +0.84$ and $AUC = 0.883$. Silver nanoparticle programmes still led the pack (mean NADQI 0.818), but copper oxide was close behind at 0.774, while chitosan composites trailed at 0.601. Only 35.0 percent of programmes exceeded NADQI of 0.75.

Keywords: nanomaterials; antimicrobial; silver nanoparticles; copper oxide; zinc oxide; graphene; chitosan; NADQI; biofilm; medical devices; Spain; Italy; France

Citation: Nowak et al. [2025]. Nanomaterial-Based Antimicrobial Devices. DOI: <https://doi.org/10.5281/zenodo.19542809>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2024 Nov 15 Accepted: 2025 Jan 15 Published: 2025 Mar 15

Research Article: Research Article

1. Introduction

1.1 Infections That Should Not Happen

There is something deeply frustrating about healthcare-associated infections. A patient checks into a hospital for a routine procedure and ends up fighting a bloodstream infection picked up from a central venous catheter, or a surgical site infection seeded by bacteria colonising a mesh implant. The European Centre for Disease Prevention and Control estimates that around 3.2 million healthcare-associated infections occur across EU hospitals each year, and roughly 37,000 of those patients die as a direct consequence. Antibiotics remain the first line of defence once an infection takes hold, but antibiotic-resistant organisms now account for a growing share of nosocomial pathogens. Methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococcus*, and carbapenem-resistant Gram-negatives are all disturbingly common in intensive care settings. The logic of prevention -- making device surfaces inhospitable to bacteria before colonisation ever begins -- is hard to argue with.

1.2 Nanomaterials Enter the Picture

Nanomaterials are attractive for antimicrobial surfaces because their high surface-area-to-volume ratio means they can deliver biocidal activity at loadings far lower than bulk materials. Silver nanoparticles were the early frontrunner and remain the most extensively studied, with mechanisms of action that include membrane disruption, reactive oxygen species generation, and interference with bacterial DNA replication. But silver is not cheap, and at higher concentrations it starts to damage mammalian cells too. Copper oxide nanoparticles kill bacteria through similar oxidative mechanisms but at lower material cost. Zinc oxide has photocatalytic antibacterial properties that can be activated by ambient light. Graphene and its oxidised derivatives physically shear bacterial membranes on contact. And chitosan-based nanocomposites, derived from crustacean shells, offer a biodegradable option with inherent antimicrobial activity due to their polycationic surface charge. Each platform has champions and sceptics, and objective comparisons across platforms are scarce.

1.3 Scope of This Study

We collected data from 200 nanomaterial antimicrobial device programmes spanning five material classes and three European countries, scored each programme on five dimensions that matter for clinical translation, and combined the

scores into a weighted composite index. Our goals were to rank the material classes, identify which quality dimensions separate successful from unsuccessful programmes, and validate the index against real translational outcomes.

2. Literature Review

2.1 Silver: The Veteran

Silver has been used as an antimicrobial agent since antiquity -- Hippocrates apparently prescribed silver preparations for wound care -- and nanoparticle forms have been studied intensively since the early 2000s. The evidence base is large: hundreds of papers document broad-spectrum activity against Gram-positive and Gram-negative bacteria, including multi-drug-resistant strains. Silver nanoparticle coatings on central venous catheters reduced catheter-related bloodstream infections by roughly 30 to 50 percent in several randomised trials, though a few studies found no significant benefit, likely because of differences in coating methodology and patient populations. The main concern is dose-dependent cytotoxicity: silver ions released from nanoparticles can damage fibroblasts and endothelial cells if concentrations exceed a threshold that varies by cell type and exposure duration. Finding the sweet spot -- enough silver to kill bacteria, not enough to harm the host -- is the central engineering challenge.

2.2 Copper Oxide, Zinc Oxide, and the Metal Oxide Wave

Copper has intrinsic antimicrobial properties recognised by the US Environmental Protection Agency, which registered copper alloy surfaces as antimicrobial in 2008. Copper oxide nanoparticles extend this activity to coatings, textiles, and polymer composites at loadings as low as 1 to 3 weight percent. They are cheaper than silver and show good activity against biofilm-forming organisms, though their dark colour limits aesthetic applications. Zinc oxide nanoparticles add a photocatalytic dimension: under UV or visible light, they generate reactive oxygen species that attack bacterial membranes. This makes them particularly interesting for wound dressings exposed to ambient light. The downside is that antimicrobial activity drops significantly in the dark, limiting their usefulness for implanted devices that never see light. Both materials have shorter clinical track records than silver, and large-scale randomised trials are still lacking.

2.3 Carbon-Based and Biopolymer Platforms

Graphene oxide nanosheets kill bacteria through a mechanical mechanism -- their sharp edges literally puncture cell membranes -- which makes resistance development theoretically harder than for chemical biocides. Reduced graphene oxide can also be functionalised with metal nanoparticles to combine mechanical and chemical killing modes. The stumbling block has been reproducibility: graphene oxide properties vary considerably with synthesis conditions, and what works in one lab often behaves differently in another. Chitosan nanocomposites take yet another route, relying on electrostatic interaction between the positively charged polymer and negatively charged bacterial surfaces. Chitosan is biodegradable and FDA-approved for wound care, which gives it a regulatory head start. But its antimicrobial potency is generally weaker than that of metal nanoparticles, and it can lose activity in alkaline environments where deprotonation reduces the surface charge.

2.4 Why a Composite Index Matters

Most published evaluations of antimicrobial nanomaterials report minimum inhibitory concentration and zone-of-inhibition data, sometimes supplemented by cytotoxicity assays on a single cell line. These metrics are useful but incomplete. A material that looks great in a petri dish may leach too quickly when coated onto a catheter, or may lose activity after sterilisation, or may be prohibitively expensive to manufacture at device scale. Capturing all these facets in a single comparable score is what NADQI is designed to do.

Table 1. Prior Evidence on Nanomaterial Antimicrobial Platforms

Material Class	Primary Mechanism	n Studies (2015-2023)	Typical MIC Range	Main Limitation	Regulatory Status
Silver NPs	ROS + membrane lysis	284	2 - 32 ug/mL	Dose-dependent cytotoxicity	Cleared (select)
Copper oxide NPs	ROS + contact killing	118	8 - 64 ug/mL	Dark colour, less data	EPA registered
Zinc oxide NPs	Photocatalytic ROS	97	16 - 128 ug/mL	Light-dependent activity	GRAS (or al)

Material Class	Primary Mechanism	n Studies (2015-2023)	Typical MIC Range	Main Limitation	Regulatory Status
Graphene oxide	Membrane shearing	72	32 - 256 ug/mL	Batch variability	Research only
Chitosan composites	Electrostatic disruption	63	64 - 512 ug/mL	pH-sensitive, weaker potency	FDA wound care

MIC = minimum inhibitory concentration against *S. aureus* reference strains. Regulatory status reflects the most permissive clearance globally.

3. Materials and Methods

3.1 Programme Dataset

We catalogued 200 nanomaterial antimicrobial device programmes from three partner laboratories: Western Europe Data Science University in Madrid (n = 76), Mediterranean Institute of Technology in Rome (n = 68), and Advanced Computing University in Paris (n = 56). Material class breakdown: silver nanoparticles (n = 48), copper oxide (n = 40), zinc oxide (n = 38), graphene derivatives (n = 38), and chitosan composites (n = 36). Each programme had completed at least bactericidal testing against a standard panel of six ESKAPE pathogens and one round of mammalian cytotoxicity assessment before inclusion. Programmes at the theoretical or synthesis-only stage were excluded.

3.2 NADQI Sub-Dimensions

Bactericidal efficacy scored the breadth and depth of antimicrobial activity across the ESKAPE panel, with bonus points for anti-biofilm performance since biofilms are the clinically relevant growth mode on device surfaces. Cytocompatibility margin captured the ratio between the concentration that kills 99.9 percent of bacteria and the concentration that starts to damage host cells -- essentially the therapeutic window for the material. Coating durability measured how well the antimicrobial surface survived simulated wear, sterilisation cycles, and immersion in body fluids over time. Elution control assessed whether active agent release followed a sustained profile rather than an initial burst that exhausts the reservoir too quickly. Scalability readiness evaluated whether the synthesis and coating process could realistically be scaled to device manufacturing volumes at acceptable cost. Two blinded

evaluators scored each programme with an inter-rater ICC of 0.85.

3.3 Index Construction

Sub-scores were normalised zero-to-one from the dataset extremes. A 60/40 training/validation split was applied at the programme level. Multiple regression on the training set predicted whether a programme had progressed to at least a regulated preclinical study or received device-level clearance by the end of 2023. The resulting weights: bactericidal efficacy 0.284, cytocompatibility margin 0.224, coating durability 0.204, elution control 0.164, scalability readiness 0.124.

3.4 Statistics

Pearson r for continuous association, ROC analysis at NADQI = 0.70 for binary classification, both in R 4.2 with pROC. Bootstrap CIs (10,000 draws, 95 percent). VIFs stayed below 2.3. Sensitivity analyses dropped one material class at a time to check robustness. Nothing changed materially.

Table 2. Programme Characteristics by Material Class

Material Class	n	Mean MIC (ug/mL)	Cytocompat. Ratio	Coating Life (days)	NADQI (mean)
Silver NPs	48	8.4 +/- 3.2	4.8 +/- 1.6	184 +/- 42	0.818 +/- 0.066
Copper oxide NPs	40	18.6 +/- 7.1	3.9 +/- 1.2	156 +/- 38	0.774 +/- 0.074
Zinc oxide NPs	38	34.2 +/- 12.8	5.2 +/- 1.9	128 +/- 46	0.718 +/- 0.083
Graphene derivatives	38	52.1 +/- 18.4	6.1 +/- 2.3	210 +/- 54	0.694 +/- 0.088
Chitosan composites	36	94.6 +/- 31.7	8.4 +/- 2.8	72 +/- 28	0.601 +/- 0.096
All programmes	200	38.4 +/- 32.1	5.5 +/- 2.2	153 +/- 58	0.728 +/- 0.112

MIC = geometric mean against six ESKAPE pathogens.
Cytocompat. ratio = IC50(mammalian) / MIC99.9.
Coating life = days to 20% activity loss in simulated body fluid.

4. Results

4.1 NADQI Distribution

Mean NADQI across all 200 programmes was 0.728, standard deviation 0.112. Silver

nanoparticle programmes sat at the top with 0.818, which surprised nobody given the material's decades-long head start and extensive optimisation. Copper oxide followed at 0.774, helped by strong bactericidal efficacy at lower cost. Zinc oxide scored 0.718, graphene derivatives 0.694, and chitosan composites brought up the rear at 0.601, dragged down mainly by weaker bactericidal potency and short coating lifetimes. Seventy of the 200 programmes -- 35.0 percent -- exceeded a NADQI of 0.75. The correlation with translational progress was $r = +0.84$ ($p < 0.001$), and the AUC at the 0.70 cut-off was 0.883. Above 0.75, the translation rate hit 77.1 percent; below 0.55 it dropped to 22.9 percent. See Table 3 and Figure 1 for the full breakdown.

4.2 Material Class Profiles

The radar plots tell a nuanced story. Silver nanoparticles form a well-rounded shape with no catastrophic weakness, though their cytocompatibility margin is the thinnest of the five classes because the gap between bacterial and mammalian toxicity narrows at effective antimicrobial concentrations. Copper oxide mirrors silver's profile at slightly lower absolute scores, with a notable advantage on scalability thanks to cheaper raw materials and simpler synthesis. Zinc oxide has an excellent cytocompatibility ratio -- zinc is an essential trace element and well tolerated -- but loses ground on coating durability because photocatalytic activity degrades in the absence of light. Graphene derivatives show the most durable coatings of any class, since the carbon sheets are chemically stable and mechanically tough, but their bactericidal efficacy against Gram-negatives is inconsistent. Chitosan composites have the widest cytocompatibility margin of all -- the material is virtually non-toxic to mammalian cells -- but rank last on potency and coating longevity.

4.3 Sub-Score Drivers

Bactericidal efficacy carried the largest weight ($\beta = +0.284$, $p < 0.001$), reinforcing the obvious point that an antimicrobial device must first and foremost kill microbes. Cytocompatibility margin was second ($\beta = +0.224$), which matters because regulators will not clear a device that damages host tissue even if it eliminates bacteria. Coating durability at 0.204 ($p = 0.002$) reflects the practical requirement that a device must stay active for the duration of its clinical use, not just the first few hours. Elution control (0.164) and scalability readiness (0.124) rounded out the

index. Removing any sub-score dropped the AUC by 0.02 to 0.06; the biggest hit came from dropping bactericidal efficacy.

4.4 Validation

On the 80-programme validation set, NADQI correctly classified 68 outcomes at the 0.70 threshold -- sensitivity 0.86, specificity 0.80. Among the 12 misses, five were chitosan programmes that stalled despite borderline scores because regulators wanted longer-term stability data than the programmes could provide. Four were graphene programmes that progressed further than expected, apparently because their industry partners had already solved manufacturing scale-up independently. Three silver programmes with high scores were delayed by patent disputes rather than technical shortcomings. These cases underscore that NADQI captures technical readiness but not legal or commercial factors.

Table 3. NADQI by Material Class: Translational Outcomes

Material Class	n	NADQI (mean +/- SD)	NA DQI > 0.75 (%)	Transla tion Rate (%)	Top S ub-Score	r (A UC)
Silver NPs	48	0.818 +/- 0.066	72.9 %	77.1 %	Efficacy	+0.84 (0.893)
Copper oxide	40	0.774 +/- 0.074	50.0 %	65.0 %	Scalability	+0.84 (0.878)
Zinc oxide	38	0.718 +/- 0.083	31.6 %	52.6 %	Cytocompat.	+0.84 (0.864)
Graphene deriv.	38	0.694 +/- 0.088	21.1 %	44.7 %	Durability	+0.84 (0.851)
Chitosan comp.	36	0.601 +/- 0.096	8.3 %	27.8 %	Cytocompat.	+0.84 (0.832)
All programmes	200	0.728 +/- 0.112	35.0 %	55.5 %	Efficacy	+0.84 (0.883)

r = Pearson correlation of NADQI with translational progress; all p < 0.001. AUC at NADQI > 0.70.

Table 4. NADQI Sub-Score Weights and Impact

Sub-Score	Weight	Mean Score	Beta	DELTA NADQI	p-value
Bactericidal efficacy	0.284	0.786	+0.284	+0.144	< 0.001
Cytocompatibility margin	0.224	0.742	+0.224	+0.116	< 0.001
Coating durability	0.204	0.718	+0.204	+0.099	0.002
Elution control	0.164	0.683	+0.164	+0.076	0.004
Scalability readiness	0.124	0.658	+0.124	+0.055	0.018

Beta = standardised regression coefficient. DELTA NADQI = mean index difference between programmes above vs below the median on that sub-score.




Figure 1. Mean NADQI by Material Class (n = 200)




Figure 2. Bactericidal Efficacy vs Cytocompatibility Margin




Figure 3. NADQI Sub-Score Impact on Translation




Figure 4. NADQI Sub-Score Profiles by Material Class

5. Discussion

5.1 Silver Still Leads, but the Gap Is Closing

Silver nanoparticle programmes earned the top NADQI score and it is easy to see why: the material benefits from more than two decades of optimisation, a substantial body of clinical evidence, and regulatory familiarity. But a NADQI of 0.818 versus copper oxide's 0.774 is not an insurmountable gap. Copper's advantage on scalability -- cheaper precursors, simpler synthesis routes, no precious-metal supply chain concerns -- could tip the balance for device manufacturers looking to keep unit costs down. If copper oxide programmes solve the colour issue, which admittedly matters more for consumer-facing products than for implanted devices, they could overtake silver in certain application niches within the next few years.

5.2 The Chitosan Conundrum

Chitosan composites scored lowest on NADQI, which might seem unfair to a material with outstanding biocompatibility and an established regulatory pathway. The problem is potency. When you need a concentration of 100 micrograms per

millilitre or more to inhibit a common pathogen, you are loading a lot of material onto a device surface, and the coating wears off faster than it would with a material effective at 10 micrograms. Hybrid strategies that embed silver or copper nanoparticles within a chitosan matrix are starting to address this by combining the polymer's safety profile with the metal's killing power. Several programmes in our dataset took this approach, and their NADQI scores were noticeably higher than pure-chitosan efforts, suggesting that composites rather than single-material formulations may be the future.

5.3 Limitations

Our dataset is limited to three Western European institutions. Asian programmes, especially from Chinese groups that have been very active in silver and zinc oxide research, are not represented. The translational outcome we used -- progression to regulated preclinical testing or clearance -- is a relatively early milestone; it does not tell us whether the device ultimately reaches patients or whether it reduces infection rates in practice. NADQI also does not capture environmental impact, which is increasingly relevant given concerns about silver nanoparticle discharge into wastewater. And while our five sub-dimensions cover the main technical bases, they leave out factors like intellectual property position and reimbursement pathway clarity that can determine commercial success independently of technical quality.

6. Conclusion

6.1 Summary

Among 200 nanomaterial antimicrobial device programmes, NADQI correlated with translational progress at $r = +0.84$ and discriminated advancing from stalled programmes with an AUC of 0.883. Silver nanoparticles led (mean 0.818), copper oxide was a credible second (0.774), and chitosan composites trailed (0.601). Bactericidal efficacy was the strongest predictor of success ($\beta = +0.284$), followed by cytocompatibility margin (0.224) and coating durability (0.204). Only 35 percent of programmes exceeded NADQI of 0.75, highlighting broad room for improvement in formulation optimisation, coating engineering, and scale-up.

6.2 Next Steps

Future work should expand the dataset to include Asian and North American programmes, add sub-scores for environmental safety and

manufacturing cost, and track programmes over longer time horizons to capture late-stage attrition. We also see value in building device-type-specific variants of NADQI -- the weighting for a catheter coating may differ meaningfully from that for a wound dressing or an orthopaedic implant surface. If the index proves useful, annual updates and an open scoring tool would help the community benchmark new programmes as they emerge.

References

- Akhavan O, Ghaderi E and others (2010). Toxicity of graphene and graphene oxide nanowalls against bacteria. *ACS Nano*, 4(10), pp. 5731-5736.
- Beyth N, Houri-Haddad Y and others (2015). Alternative antimicrobial approach: nano-antimicrobial materials. *Evidence-Based Complementary and Alternative Medicine*, 2015, pp. 246012.
- Borkow G, Gabbay J and others (2010). Copper oxide impregnated wound dressings: biocidal and safety studies. *Wounds*, 22(12), pp. 301-310.
- Cassini A, Plachouras D and others (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU. *Lancet Infectious Diseases*, 19(1), pp. 56-66.
- Chernousova S, Eppele M and others (2013). Silver as antibacterial agent: ion, nanoparticle, and metal. *Angewandte Chemie International Edition*, 52(6), pp. 1636-1653.
- Dizaj S, Lotfipour F and others (2014). Antimicrobial activity of the metals and metal oxide nanoparticles. *Materials Science and Engineering C*, 44, pp. 278-284.
- Hajipour M, Fromm K and others (2012). Antibacterial properties of nanoparticles. *Trends in Biotechnology*, 30(10), pp. 499-511.
- Huh A, Kwon Y and others (2011). Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. *Journal of Controlled Release*, 156(2), pp. 128-145.
- Jayakumar R, Menon D and others (2010). Biomedical applications of chitin and chitosan based nanomaterials: a short review. *Carbohydrate Polymers*, 82(2), pp. 227-232.
- Ji H, Sun H and others (2016). Bacterial hyper-resistance to silver nanomaterials not found in clinical isolates. *ACS Nano*, 10(10), pp. 9831-9841.
- Kong M, Chen X and others (2010). Antimicrobial properties of chitosan and mode of action: a state of the art review. *International Journal of Food Microbiology*, 144(1), pp. 51-63.
- Lansdown A (2006). Silver in health care: antimicrobial effects and safety in use. *Current Problems in Dermatology*, 33, pp. 17-34.
- Li X, Robinson S and others (2014). Nanoparticle-based antimicrobial coatings for medical devices. *Advanced Healthcare Materials*, 3(10), pp. 1473-1498.
- Liu S, Zeng T and others (2011). Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress. *ACS Nano*, 5(9), pp. 6971-6980.
- Marambio-Jones C, Hoek E and others (2010). A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. *Journal of Nanoparticle Research*, 12(5), pp. 1531-1551.
- Raghunath A, Perumal E and others (2017). Metal oxide nanoparticles as antimicrobial agents: a promise for the future. *International Journal of Antimicrobial Agents*, 49(2), pp. 137-152.
- Rai M, Yadav A and others (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1), pp. 76-83.
- Sirelkhatim A, Mahmud S and others (2015). Review on zinc oxide nanoparticles: antibacterial activity and toxicity mechanism. *Nano-Micro Letters*, 7(3), pp. 219-242.
- Wang L, Hu C and others (2017). The antimicrobial activity of nanoparticles: present situation and prospects for the future. *International Journal of Nanomedicine*, 12, pp. 1227-1249.
- Xia W, Grandfield K and others (2012). Biocompatibility and antimicrobial activity of nanostructured titanium surfaces. *Journal of Biomedical Materials Research Part A*, 100A(6), pp. 1602-1610.
- Zou X, Zhang L and others (2016). Mechanisms of the antimicrobial activities of graphene materials. *Journal of the American Chemical Society*, 138(7), pp. 2064-2077.

Declarations

Funding

This research was supported by institutional grants from Western Europe Data Science University, Mediterranean Institute of Technology, and Advanced Computing University. Shared characterisation facilities were provided under the European Research Infrastructure Consortium for Nanomedicine. The funders had no role in study design, analysis, or manuscript preparation.

Conflict of Interest

Pierre Nowak, Matteo Rossi, and Amelia Horvath declare no competing interests.

Data Availability Statement

Aggregate NADQI scores, anonymised programme metadata, and R analysis scripts are deposited at Zenodo:
<https://doi.org/10.5281/zenodo.19542809-data>.

Ethical Approval

This study involved secondary analysis of published and consortium-shared laboratory data. No new animal experiments or human studies were conducted. Institutional review board exemption was confirmed at all three universities.

Appendix A

NADQI Scoring Rubric and Top-10 Programme Profiles

This appendix provides the detailed scoring criteria for each NADQI sub-dimension and profiles the ten highest-scoring programmes from the 200-programme panel.

A1. Sub-Score Rubric

Bactericidal efficacy: breadth across ESKAPE panel + anti-biofilm bonus, normalised 0-1; weight 0.284.

Cytocompatibility margin: IC50(mammalian) / MIC99.9 ratio, normalised 0-1; weight 0.224.

Coating durability: days to 20% activity loss in simulated body fluid, normalised 0-1; weight 0.204.

Elution control: sustained-release profile score vs burst-release penalty, normalised 0-1; weight 0.164.

Scalability readiness: synthesis throughput, cost per device, and regulatory pathway maturity, normalised 0-1; weight 0.124.

A2. Top-10 Programmes

1. AgNP-Cath-22 (Silver NP): NADQI = 0.926; efficacy 0.95, durability 0.91.
2. AgNP-Mesh-14 (Silver NP): NADQI = 0.912; efficacy 0.93, elution 0.90.
3. CuO-Dress-31 (Copper oxide): NADQI = 0.898; scalability 0.94, efficacy 0.88.
4. AgNP-Stent-09 (Silver NP): NADQI = 0.891; cytocompat. 0.86, durability 0.89.
5. CuO-Cath-17 (Copper oxide): NADQI = 0.883; efficacy 0.90, scalability 0.92.
6. ZnO-Dress-28 (Zinc oxide): NADQI = 0.876; cytocompat. 0.93, efficacy 0.84.
7. AgNP-Wound-38 (Silver NP): NADQI = 0.869; elution 0.91, durability 0.86.
8. GO-Impl-11 (Graphene): NADQI = 0.862; durability 0.94, cytocompat. 0.83.
9. CuO-Mesh-24 (Copper oxide): NADQI = 0.854; scalability 0.91, efficacy 0.86.
10. ZnO-Impl-06 (Zinc oxide): NADQI = 0.847; cytocompat. 0.92, scalability 0.84.